Today: 21 May 2026
Browse Category

ASX:CBA 10 February 2026 - 18 May 2026

Apellis Stock Delisted From Nasdaq, Focus Turns to $4 Payout

Apellis Stock Delisted From Nasdaq, Focus Turns to $4 Payout

National Australia Bank shares closed down 0.55% at A$36.32 on Monday as the S&P/ASX 200 hit a seven-week low. NAB has dropped in four of the past five sessions, following a weaker-than-expected first-half profit and a A$706 million credit impairment charge. Broader market losses were driven by inflation fears and weak global equities. Investors remain cautious after recent sharp declines in major Australian banks.
18 May 2026
····
Australia Stock Market Today: ASX 200 Falls as Banks Drop Before Budget, Miners Rally on Copper

Australia Stock Market Today: ASX 200 Falls as Banks Drop Before Budget, Miners Rally on Copper

The S&P/ASX 200 fell 0.36% to 8,670.7 on Tuesday, led lower by banks, tech stocks, and CSL ahead of the federal budget. ANZ and NAB dropped 2.1% each, while Life360 plunged 10.9% after a user-growth glitch despite strong revenue. DroneShield slid 9.9% after disclosing an ASIC probe. Miners rose, with BHP up 2.5% as copper hit a record high.
12 May 2026
········
ASX 200 Weekly Report: Australia Stocks Barely Rise After Oil Shock Turns Friday Into a $50 Billion Rout

ASX 200 Weekly Report: Australia Stocks Barely Rise After Oil Shock Turns Friday Into a $50 Billion Rout

Australian shares lost nearly A$50 billion in value Friday as the S&P/ASX 200 fell 1.51% to 8,744.4, its biggest one-day drop in seven weeks. The Reserve Bank of Australia raised rates to 4.35% Tuesday, citing rising fuel prices and Middle East risks. Financials led declines, with Westpac down 4.8%. Macquarie Group posted a record A$4.85 billion profit but closed lower.
9 May 2026
·····
Australia Stock Market Today: ASX 200 Falls Again as Oil Shock, Woolworths Warning Hit Shares

Australia Stock Market Today: ASX 200 Falls Again as Oil Shock, Woolworths Warning Hit Shares

Australian shares fell for an eighth straight session Thursday, with the S&P/ASX 200 closing down 0.24% at 8,665.8 as miners and consumer staples dropped. The decline followed data showing annual inflation rose to 4.6% in March, above the Reserve Bank’s target. Woolworths shares slid up to 9.8% after warning on earnings. Oil prices hit a four-year high, lifting energy stocks 1.4%.
30 April 2026
···
Australia Stock Market Today: ASX 200 Stalls as Rio Tinto Gain Runs Into Energy Selloff

Australia Stock Market Today: ASX 200 Stalls as Rio Tinto Gain Runs Into Energy Selloff

Australian shares closed nearly flat Tuesday, with the S&P/ASX 200 down 3.9 points to 8,949.40 as investors awaited U.S.-Iran talks. Rio Tinto rose after reporting a 9% jump in first-quarter copper-equivalent output, but energy stocks fell. Brent crude traded near $95 a barrel, and the Australian dollar slipped to $0.715. ANZ reported consumer confidence at 64.3, near record lows, with inflation expectations at 7.1%.
21 April 2026
···········
Australia Stock Market Today: ASX 200 Drops 1.3% as $100 Oil Revives RBA Rate-Hike Fears

Australia Stock Market Today: ASX 200 Drops 1.3% as $100 Oil Revives RBA Rate-Hike Fears

Australian shares fell 1.3% Thursday, with the S&P/ASX 200 closing at 8,629.00 after oil surged above $100 a barrel following attacks on Middle East fuel tankers. Financials dropped 1.5% and miners 1.7%, while energy stocks rose sharply. Traders now see a 75% chance of another Reserve Bank rate hike next week. The index is down over 6% in March, on track for its worst month since September 2022.
12 March 2026
······
Australian Securities Exchange Weekly Wrap: ASX 200 Sheds A$130 Billion as Middle East War and Rate Risks Rattle Stocks

Australian Securities Exchange Weekly Wrap: ASX 200 Sheds A$130 Billion as Middle East War and Rate Risks Rattle Stocks

Australian shares lost 3.8% last week, erasing about A$130 billion in value as the Middle East conflict rattled markets. Miners fell 4.1%, gold miners 4.3%, while energy stocks rose 0.2% on surging oil prices. The Reserve Bank of Australia signaled a “live meeting” for March 17 as inflation risks mount. Economic growth beat forecasts, rising 0.8% in Q4.
7 March 2026
···
Commonwealth Bank of Australia share price slips as GDP data lifts RBA rate-hike nerves

Commonwealth Bank of Australia share price slips as GDP data lifts RBA rate-hike nerves

Commonwealth Bank of Australia shares fell 1.6% to A$171.13 Wednesday as financial stocks slid amid renewed rate-hike fears and rising oil prices. Australia’s economy grew at its fastest annual pace in nearly three years, prompting speculation the Reserve Bank could raise rates as soon as March. Investors await the RBA’s March 16–17 policy meeting and April inflation data.
4 March 2026
·
ASX 200 today: Australian shares finish flat as AI fears hit insurers; CSL slides 5%

ASX 200 today: Australian shares finish flat as AI fears hit insurers; CSL slides 5%

The S&P/ASX 200 closed down 2.7 points at 8,867.40, as insurance brokers slumped on AI competition fears. CSL dropped 5% after announcing CEO Paul McKenzie's retirement. Treasury Wine Estates surged over 8% on a U.S. dispute settlement and upgraded earnings forecast. Investors await key earnings from Commonwealth Bank and CSL on Wednesday.
10 February 2026
······
Commonwealth Bank (CBA) share price slips ahead of results: margins and dividend in focus

Commonwealth Bank (CBA) share price slips ahead of results: margins and dividend in focus

Commonwealth Bank of Australia shares fell 0.7% to A$158.74 Tuesday as investors trimmed positions before the bank’s half-year results due Wednesday. Bank stocks weighed on the S&P/ASX 200, which closed nearly flat. CBA has flagged a A$68 million provision and A$53 million in non-recurring items. Investors are focused on margins, costs, and the interim dividend timetable.
10 February 2026
··
1 2 3 … 7

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop